...
首页> 外文期刊>Arteriosclerosis, thrombosis, and vascular biology >Ser-Phosphorylation of PCSK9 (Proprotein Convertase Subtilisin-Kexin 9) by Fam20C (Family With Sequence Similarity 20, Member C) Kinase Enhances Its Ability to Degrade the LDLR (Low-Density Lipoprotein Receptor)
【24h】

Ser-Phosphorylation of PCSK9 (Proprotein Convertase Subtilisin-Kexin 9) by Fam20C (Family With Sequence Similarity 20, Member C) Kinase Enhances Its Ability to Degrade the LDLR (Low-Density Lipoprotein Receptor)

机译:PCSK9(Proprotein转化酶枯草杆菌蛋白酶-Kexin 9)的Ser-磷酸化通过FAM20C(具有序列相似性20,成员C)激酶增强其降解LDLR的能力(低密度脂蛋白受体)

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: PCSK9 (proprotein convertase subtilisin-kexin 9) enhances the degradation of the LDLR (low-density lipoprotein receptor) in endosomes/lysosomes. This study aimed to determine the sites of PCSK9 phosphorylation at Ser-residues and the consequences of such posttranslational modification on the secretion and activity of PCSK9 on the LDLR. Approach and Results: Fam20C (family with sequence similarity 20, member C) phosphorylates serines in secretory proteins containing the motif S-X-E/phospho-Ser, including the cholesterol-regulating PCSK9. In situ hybridization of Fam20C mRNA during development and in adult mice revealed a wide tissue distribution, including liver, but not small intestine. Here, we show that Fam20C phosphorylates PCSK9 at Serines 47, 666, 668, and 688. In hepatocytes, phosphorylation enhances PCSK9 secretion and maximizes its induced degradation of the LDLR via the extracellular and intracellular pathways. Replacing any of the 4 Ser by the phosphomimetic Glu or Asp enhanced PCSK9 activity only when the other sites are phosphorylated, whereas Ala substitutions reduced it, as evidenced by Western blotting, Elisa, and LDLR-immunolabeling. This newly uncovered PCSK9/LDLR regulation mechanism refines our understanding of the implication of global PCSK9 phosphorylation in the modulation of LDL-cholesterol and rationalizes the consequence of natural mutations, for example, S668R and E670G. Finally, the relationship of Ser-phosphorylation to the implication of PCSK9 in regulating LDL-cholesterol in the neurological Fragile X-syndrome disorder was investigated. Conclusions: Ser-phosphorylation of PCSK9 maximizes both its secretion and activity on the LDLR. Mass spectrometric approaches to measure such modifications were developed and applied to quantify the levels of bioactive PCSK9 in human plasma under normal and pathological conditions.
机译:目的:PCSK9(ProProtein转化酶枯草杆菌素-Kexin 9)增强了LDLR(低密度脂蛋白受体)在内体/溶酶体中的降解。该研究旨在确定Ser-Resides的PCSK9磷酸化位点及其在LDLR上PCSK9分泌和活性的后果。方法和结果:FAM20C(具有序列相似性20,成员C)磷酸化含有胆固醇调节PCSK9的分泌蛋白中的分泌蛋白质中的丝氨酸。在发育期间和成人小鼠期间对FAM20C mRNA的原位杂交揭示了一种宽的组织分布,包括肝脏,但不是小肠。这里,我们表明FAM20C磷酸化PCSK9在丝氨酸47,666,668和688。在肝细胞​​中,磷酸化增强了PCSK9分泌,并通过细胞外和细胞内途径最大化其诱导的LDLR降解。只有当其他网站磷酸化时,才通过磷光磷酸纤维素或ASP的任何4个SER中的任何一种,而ALA取代可以减少它,如Western印迹,ELISA和LDLR-IMMUTOLING所证明。这种新发现的PCSK9 / LDLR调节机制改善了我们对全球PCSK9磷酸化在LDL-胆固醇调节中的含义的理解,并可合理化自然突变的后果,例如S668R和E670G。最后,研究了Ser-磷酸化与PCSK9在神经脆性X-综合征病症中调节LDL-胆固醇的影响的关系。结论:PCSK9的Ser-磷酸化最大化其在LDLR上的分泌和活性。显影并应用测量这些修饰的质谱方法,以在正常和病理条件下量化人血浆中的生物活性PCSK9水平。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号